Incyte (INCY)

Healthcare · Biotechnology · S&P 500
$112.73 -1.23% on the day Market cap $21.8B 52-week range $82.82 to $132.60 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Incyte's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

A

Five factors scored 1 to 9 from INCY's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability9
Growth8
Financial health8

Key numbers

P/E (trailing)15.4x
P/E (forward)14.1x
Price / free cash flow16.1x
EV / EBITDA9.49x
Price / sales4.06x
Price / book3.86x
Revenue growth+20.9%
Operating margin30.1%
Net margin26.7%
Return on equity25.5%
Dividend yield—
Debt / equity0.31x

Results from SEC filings

Fiscal years, from Incyte's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$3.0B$3.4B$3.7B$4.2B$5.1B
Net income$949M$341M$598M$33M$1.3B
Free cash flow$568M$892M———
EPS (diluted)$4.27$1.52$2.65$0.15$6.41
Operating margin19.6%17.1%16.8%1.4%29.5%

Where the revenue comes from

Revenue by products, fiscal 2025.

JAKAFI$3.1B60%
OPZELURA$678M13%
JAKAVI Royalty Revenues$458M9%
NIKTIMVO$152M3%
Milestone and contract revenues$150M3%
OLUMIANT Royalty Revenues$145M3%

Superinvestors who own INCY

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Dodge & Cox
Dodge & Cox
Trimmed $1.4B0.71%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $603M0.21%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $82M0.19%Q2 2026

Insider buying

Open-market purchases by Incyte's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Mar 30, 2026 Ro Khanna
0$90.33—
Mar 30, 2026 Ro Khanna
0$90.33—
Jan 29, 2026 Ro Khanna
0$101.08—
Jan 29, 2026 Ro Khanna
0$101.08—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when INCY trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Incyte insiders buying the stock?

4 open-market insider purchases of INCY in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Incyte?

3 of the superinvestors Investingly tracks hold INCY in their latest 13F, including Dodge & Cox, Cliff Asness, Joel Greenblatt.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.